Related Experiment Videos
Recombinant human gamma-interferon in primary hepatocellular carcinoma
Journal of the Royal Society of Medicine
|October 1, 1985
Summary
Recombinant human gamma-interferon showed unacceptable toxicity and no response in patients with primary liver cancer. The phase II trial was stopped early due to severe renal adverse events and faster disease progression.
Area of Science:
- Hepatology
- Oncology
- Immunotherapy
Background:
- Primary hepatocellular carcinoma (HCC) is a significant global health concern.
- Limited effective treatments exist for unresectable HCC.
- Interferon-based therapies have been explored for various cancers.
Purpose of the Study:
- To evaluate the efficacy and safety of recombinant human gamma-interferon (IFN-γ) in patients with unresectable primary HCC.
- To assess treatment response and toxicity profile of IFN-γ therapy.
Main Methods:
- A phase II clinical trial was conducted.
- Seven patients with unresectable primary HCC were recruited.
- Treatment involved recombinant human gamma-interferon.
Main Results:
- The trial was prematurely terminated due to unacceptable toxicity, primarily renal.
- No objective tumor response was observed in any of the seven patients.
- Evidence suggested a more rapid disease progression during IFN-γ treatment.
Conclusions:
- Recombinant human gamma-interferon is not an effective treatment for unresectable primary HCC.
- Significant renal toxicity limits its therapeutic potential.
- Further investigation into IFN-γ for HCC is not warranted based on these findings.